Phase IIb AMP Studies: In Vitro Susceptibility of HIV-1 Isolates to Broadly Neutralizing Antibody VRC01 Predicts HIV Prevention Efficacy in MSM, Transgender Persons, and Cisgender Women

January 27-28 and February 3-4, 2021
This pooled analysis of the phase IIb AMP studies observed that in vitro susceptibility of circulating HIV-1 isolates to the broadly neutralizing antibody, VRC01, predicts prevention efficacy in MSM, transgender persons, and cisgender women.
Format: Microsoft PowerPoint (.ppt)
File Size: 292 KB
Released: February 3, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Produced in collaboration with
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

CCO expert commentary on key studies from HIVR4P // Virtual 2021 on PrEP, implementation strategies, multipurpose prevention technologies, and more

Kenneth Mayer, MD Released: February 25, 2021

Commentary from Dr. Kenneth Mayer on data from HIVR4P 2021 on immunoprophylaxis and multipurpose prevention as PrEP, from Clinical Care Options (CCO)

Kenneth Mayer, MD Released: February 18, 2021

Expert selections of the most important data from HIVR4P 2021 Virtual, including PrEP clinical trials, implementation strategies and more, from CCO

Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD Kenneth Mayer, MD Released: February 17, 2021

Commentary from Dr. Beatriz Grinsztejn on new data from HIVR4P 2021 on long-acting PrEP islatravir and cabotegravir, from Clinical Care Options (CCO)

Beatriz Grinsztejn, MD, PhD Released: February 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue